Abstract

Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Late-Breaking Science Abstracts From the American Heart Association's Scientific Sessions 2018 and Late-Breaking Abstracts in Resuscitation Science From the Resuscitation Science Symposium 2018.
-
Circulation | VOL. 138
--
18 Dec 2018
481-P: Eligibility for Icosapent Ethyl in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: An Analysis of VERTIS CV
Joseph M Kim ... Robert Frederich
Diabetes | VOL. 71
Joseph M Kim, et. al.Joseph M Kim ... Robert Frederich
01 Jun 2022
Joint statement from the European Atherosclerosis Society and European Society of Vascular Medicine focuses on patients with peripheral arterial disease
Jane K Stock
Atherosclerosis | VOL. 340
Jane K StockJane K Stock
26 Nov 2021
Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics.
Kausik K Ray ... Thomas F Lüscher
European heart journal | VOL. 41
Kausik K Ray, et. al.Kausik K Ray ... Thomas F Lüscher
23 Dec 2019
View more papers

More From: Diabetes, obesity & metabolism

Paper Title
Journal
Date
Author
A phase 1, randomized, double-blind, placebo-controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects.
Panpan Xie ... Aixin Shi
Diabetes, obesity & metabolism | VOL. -
Panpan Xie, et. al.Panpan Xie ... Aixin Shi
29 May 2024
Machine learning for prediction of chronic kidney disease progression: Validation of the Klinrisk model in the CANVAS Program and CREDENCE trial.
Navdeep Tangri ... Brendon L Neuen
Diabetes, obesity & metabolism | VOL. -
Navdeep Tangri, et. al.Navdeep Tangri ... Brendon L Neuen
28 May 2024
What every clinician needs to know about chronic kidney disease: Detection, classification and epidemiology.
Nicholas M Selby ... Maarten W Taal
Diabetes, obesity & metabolism | VOL. -
Nicholas M Selby, et. al.Nicholas M Selby ... Maarten W Taal
28 May 2024
Depression and type 2 diabetes: A causal relationship and mechanistic pathway.
Wael Y Khawagi ... Gaber El-Saber Batiha
Diabetes, obesity & metabolism | VOL. -
Wael Y Khawagi, et. al.Wael Y Khawagi ... Gaber El-Saber Batiha
27 May 2024
View more papers